Abstract
The gradual alignment with all of drug metabolism with all aspects of drug discovery and development has led to a complete realignment of the way the work is conducted. From a background of conducting bespoke in vivo studies much of the work is now in a high throughput screening mode. Large technological advances have been made, but the nature of drug metabolism processes, being multi-system and promiscuous means that much of the help provided to the medicinal chemistry is reactive rather than based on fundamental disposition structure-activity relationships. Lessons learned around the chemical and physicochemical properties more often associated with succesfull discovery and development projects are only moderately helpful when the high value pharmacological targets of today only yield potent ligands outside of the boundaries these properties describe. Pivotal to the impact of these properties is the intrinsic permeability of a molecule, something not as widely recognised as perhaps it should be. Metabolic lability is still a problem and the tactics employed are unchanged in 20 years: attempt to lower lipophilicity, if it is too high overall or introduce blocking groups, particularly halogens, after identifying the sites of metabolism Perhaps the greatest success drug metabolism science has had over the last fifteen years is its pivotal role in characterising drug-drug interactions and providing screening systems and computational models to investigate them. It still has many undeveloped areas of the science such as the role of metabolites in drug activity and why compounds vary in their extent of biliary excretion.
Keywords: Screening, CYP450, transporters, permeability, bile, metabolites, physicochemistry
Current Topics in Medicinal Chemistry
Title: Discovery and ADMET: Where Are We Now
Volume: 11 Issue: 4
Author(s): Dennis A. Smith
Affiliation:
Keywords: Screening, CYP450, transporters, permeability, bile, metabolites, physicochemistry
Abstract: The gradual alignment with all of drug metabolism with all aspects of drug discovery and development has led to a complete realignment of the way the work is conducted. From a background of conducting bespoke in vivo studies much of the work is now in a high throughput screening mode. Large technological advances have been made, but the nature of drug metabolism processes, being multi-system and promiscuous means that much of the help provided to the medicinal chemistry is reactive rather than based on fundamental disposition structure-activity relationships. Lessons learned around the chemical and physicochemical properties more often associated with succesfull discovery and development projects are only moderately helpful when the high value pharmacological targets of today only yield potent ligands outside of the boundaries these properties describe. Pivotal to the impact of these properties is the intrinsic permeability of a molecule, something not as widely recognised as perhaps it should be. Metabolic lability is still a problem and the tactics employed are unchanged in 20 years: attempt to lower lipophilicity, if it is too high overall or introduce blocking groups, particularly halogens, after identifying the sites of metabolism Perhaps the greatest success drug metabolism science has had over the last fifteen years is its pivotal role in characterising drug-drug interactions and providing screening systems and computational models to investigate them. It still has many undeveloped areas of the science such as the role of metabolites in drug activity and why compounds vary in their extent of biliary excretion.
Export Options
About this article
Cite this article as:
A. Smith Dennis, Discovery and ADMET: Where Are We Now, Current Topics in Medicinal Chemistry 2011; 11 (4) . https://dx.doi.org/10.2174/156802611794480909
DOI https://dx.doi.org/10.2174/156802611794480909 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
Current Cancer Therapy Reviews History and Global Status of the New Coronavirus Covid-2019 and Aspects of Previous Infections of SARS-CoV and MERS-CoV: A Systematic Review
Coronaviruses Heart Failure Pharmacotherapy and Supports in the Elderly - A Short Review
Current Cardiology Reviews Fibromyalgia: The Prototypical Central Sensitivity Syndrome
Current Rheumatology Reviews The Role of P-Glycoprotein in Psychiatric Disorders: A Reliable Guard of the Brain?
Central Nervous System Agents in Medicinal Chemistry Non-Analgesic Effects of Opioids: Cardiovascular Effects of Opioids and their Receptor Systems
Current Pharmaceutical Design Novel Anti-arrhythmic Medications in the Treatment of Atrial Fibrillation
Current Cardiology Reviews Monoaminergic Neurotransmission: The History of the Discovery of Antidepressants from 1950s Until Today
Current Pharmaceutical Design Machine Learning Approaches in Parkinson’s Disease
Current Medicinal Chemistry Endoplasmic Reticulum Stress and Atherosclerosis
Current Hypertension Reviews Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry Ribosome-inactivating Proteins from Root Tubers and Seeds of Trichosan-thes kirilowii and Other Trichosanthes Species
Protein & Peptide Letters Recent Advances in the MCRs Synthesis of Chromenes: A Review
Current Organic Chemistry Pharmacological Properties and Therapeutic Possibilities for Drugs Acting Upon Endocannabinoid Receptors
Current Drug Targets - CNS & Neurological Disorders The Medical Complications of Anorexia Nervosa and Their Treatments
Current Women`s Health Reviews Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Prevalence of Pre-Existing Risk Factors for Adverse Events Associated with Atypical Antipsychotics Among Commercially Insured and Medicaid Insured Patients Newly Initiating Atypical Antipsychotics
Current Drug Safety Current Metabolomic Methodologies & their Application to Thermal Stress
Current Metabolomics The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias
Current Neuropharmacology Cardiorenal Consequences of Atherosclerosis and Statins Therapy: From the Past to the Future
Current Pharmaceutical Design